A kind of purification method of Neratinib
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG HISUN PHARMA CO LTD
- Publication Date
- 2018-10-26
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the technical field of medicinal chemistry and crystallization, and in particular relates to a purification method of neratinib. Background technique
[0002] Neratinib, chemical name: (E)-N-[4-[3-chloro-4-(pyridine-2-methoxy)anilino]-3-cyano-7-ethoxy Quinolin-6-yl]-4-dimethylamino-2-butenamide, the structure of which is shown in Formula 1 below. Neratinib is a drug developed by Puma Biotechnology Company of the United States for the treatment of breast cancer. It is a highly selective human epidermal growth factor receptor (EGFR) and HER-2 inhibitor. Clinical studies have shown that neratinib is significantly more effective than Roche's Herceptin in the treatment of early HER-2 positive breast cancer.
[0003]
[0004] The impurities of neratinib are very similar to the structure and properties of neratinib, and their solubility in common organic solvents is very small, making it difficult to purify and separate. WO20061...